ABU-DHABI-SECURITIES
14.1.2020 18:05:11 CET | Business Wire | Press release
ADX is participating in the "Second Abu Dhabi Sustainable Finance Forum" held under the umbrella of "Abu Dhabi Sustainability Week 2020", one of the world's most prominent sustainability events which takes place in the capital Abu Dhabi from 11th to 18th of January 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200114005680/en/
ADX is one of the signatories of the "Abu Dhabi Sustainable Finance Declaration", and a member of the "United Nations Sustainable Stock Exchange Initiative" (SSE). Today, Abu Dhabi Securities Exchange (ADX) announced that it will issue its first Environmental, Social & Governance (ESG) report in the first half of 2020. The report will be issued annually and is the first of its kind in the region.
The announcement comes few months after ADX issued a set of ESG disclosure guidelines to encourage listed companies to follow its lead and incorporate ESG issues into their business to test their effectiveness and act upon it. This will encourage listed companies to issue their sustainability reports, and it illustrates ADX’s commitment to drive sustainability in financial markets.
ADX is looking forward to an active participation in the discussions of the forum, which serves as an important opportunity to meet with different leaders around the world. ADX will discuss ways to integrate sustainability within the regulatory frameworks of investment institutions and cooperation with local and international sector leaders. This will enhance communication, knowledge and awareness in the field of sustainable financing, and will also help to explore Current and future opportunities for both sustainable finance and capital investment sectors, to obtain positive economic, social and environmental outcomes.
H.E. Khalifa Salem Al Mansouri, Chief Executive of ADX , said: “One of ADX’s strategic objectives is to advance Sustainable Development Goals (SDGs) through Sustainable Finance. Today I am proud to announce that ADX will release its first annual Environmental, Social & Governance (ESG) report in the first half of 2020. The report is instrumental in advancing our Sustainable Finance Agenda and promoting high sustainability standards. It also marks a significative step towards enhancing ADX's competitiveness and attracting more sustainable investments to Abu Dhabi.”
His Excellency continued: "In line with the growing investments made to companies that implements environmental, social and corporate governance, we aim to develop and position ADX as a vibrant and thriving sustainable investment hub that supports capital formation, raising and deployment as well as the creation and issuance of products to achieve positive economic, social and environmental objectives.”
His Excellency added: “Companies' commitments to developing strategies that integrate the standards of the report opens the way for investments supported by US$83 Trillion from various Asset Management Funds (AMC). These funds will be directed to companies that apply environmental, social and corporate governance standards. New Financial instruments and policies are among the instrumental components that will make up sustainable finance and ADX’s ESG report will encourage the business community to adopt practices that achieve environmental and social sustainability standards."
By adopting these high standards, ADX is in harmony with “Towards the next 50” that charts out the UAE’s strategic development plan which aims to build a sustainable, diversified and high value-added economy that positively contributes to transition to a new global sustainable development paradigm. ADX’s ESG report reinforces the guiding principles on Sustainable Finance and encourages building up investment opportunities while increasing the quality and depth of sustainable investments in the UAE.
About Abu Dhabi Securities Exchange:
Abu Dhabi Securities Exchange (ADX) was established on November 15 of the year 2000 by Local Law No. (3) Of 2000, the provisions of which vest the market with a legal entity of autonomous status, independent finance and management. The Law also provides ADX with the necessary supervisory and executive powers to exercise its functions.
ADX is a market for trading securities; including shares issued by public joint stock companies, bonds issued by governments or corporations, exchange traded funds, and any other financial instruments approved by the UAE Securities and Commodities Authority (SCA).
In 2014, ADX was upgraded to ‘Emerging Market’ status by both MSCI and S&P Dow Jones. ADX was already classified as an Emerging Market by FTSE in 2009 and in 2011 by S&P and Russell Investments.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20200114005680/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom